Immediate steps for primary care clinicians receiving a newborn’s positive screen result
Introduction
Classic galactosemia is an inborn error of carbohydrate metabolism caused by a severe deficiency of the galactose-1-phosphate uridylyltransferase (GALT) enzyme, which disrupts the body’s ability to metabolize the sugar galactose. This block in the Leloir pathway leads to the rapid toxic accumulation of galactose-1-phosphate, galactose, and galactitol following the ingestion of breast milk or lactose-containing formula. Neonates typically present within the first few days of life with life-threatening symptoms, including poor feeding, vomiting, profound jaundice, hepatomegaly, and a high susceptibility to Escherichia coli neonatal sepsis. Acute symptoms respond well to dietary restriction of lactose, but individuals remain at a high risk for long-term complications, including developmental delays, speech dyspraxia, ataxia, and premature ovarian insufficiency (POI) in females. While variant forms of galactosemia (such as Duarte variant) and other types caused by galactokinase (GALK) or uridine diphosphate galactose-4-epimerase (GALE) deficiencies exist, they represent separate clinical entities not addressed in this article.
Other names: GALT deficiency, Galactose-1-phosphate uridylyltransferase deficiency, Galactosemia type 1
Keywords: Galactose, galactosemia, lactose, liver failure, inborn error of metabolism, newborn screening, primary ovarian insufficiency
Disorder Category
Galactosemia
Abnormal Finding
Deficiency of galactose-1-phosphate uridylyltransferase (GALT) enzyme activity
Tested By
Semiquantitative, fluorometric GALT enzyme assay
Results may be compromised by excess heat exposure to the sample, resulting in a false positive, or compromised by transfusion prior to specimen collection, resulting in a false negative.
Clinical Characteristics
For classic galactosemia, symptoms develop shortly after ingestion of milk or other lactose-containing products. In most cases, this will occur before newborn screening results are available as a life-threatening emergency in a neonate presenting with poor feeding, vomiting, profound jaundice, hepatomegaly, and bleeding diathesis.
With treatment, life-threatening acute metabolic complications can be prevented. However, despite early and adequate therapy, a significant subset of individuals with classic galactosemia will still experience long-term neurodevelopmental complications. These include speech defects (predominantly childhood apraxia of speech), cognitive impairments, and progressive neurological deficits such as ataxia, tremors, and extrapyramidal findings. Additionally, premature ovarian insufficiency (POI) develops in the vast majority of females, severely compromising fertility, though rare instances of spontaneous or assisted conception have occurred. In contrast, males generally exhibit normal pubertal development and preserved fertility, though some can demonstrate abnormalities in semen parameters.
Without treatment, ingestion of lactose leads to rapid clinical deterioration and a high risk of neonatal mortality.
Initial signs/symptoms of galactosemia may include:
- Poor feeding
- Vomiting
- Diarrhea
- Jaundice
- Bleeding diathesis
- Lethargy
- Hepatomegaly
- Failure to thrive
- Increased risk of sepsis with gram-negative organisms
If not treated promptly (first 7 days of life), patients may experience:
- Progressive liver failure
- Severe brain damage
- Death
Incidence
Classic galactosemia occurs in about 1 in 30,000 live births; Duarte variant occurs in about 1 in 16,000.1
Inheritance
Autosomal recessive – Genetic testing is possible for at-risk family members if both disease-causing mutations of an affected family member have been identified.
Next Steps After a Positive Screen
- Contact the family and evaluate the infant for related symptoms.
- Provide same-day emergency treatment and referral to Biochemical Genetics (Metabolics) for any symptoms of poor feeding, lethargy, jaundice, bleeding, bulging fontanel, and vomiting. Severity may be screened rapidly with liver function tests (LFTs), prothrombin time with international normalized ratio (PT/INR), and urine reducing substance assay.
- Discontinue all breastmilk and lactose-containing formula feeds. Start soy formula (e.g., Prosobee or Isomil) feeds immediately.
- Patients with a positive screening test or who are symptomatic should be on a lactose/galactose-free diet until GALT enzyme activity and galactosemia DNA panel results are available.
Confirming the Diagnosis
- To confirm the diagnosis, work with Newborn Screening Services.
- Follow-up testing will involve galactose-1-phosphate uridyltransferase activity, red cell Gal-1-P, and GALT gene sequencing.
- In classic galactosemia, GALT activity is absent or barely detectable, and Gal-1-P is markedly elevated.
- Clinical variant galactosemia tends to have less remarkable elevations of Gal-1-P or, in some cases, may even be in the normal range, but GALT activity will still be significantly reduced to ~1%.
- With biochemical variant (e.g., Duarte) or carrier status, the GALT activity is moderately reduced to approximately 25% or greater compared to controls and Gal-1-P range from normal to mildly elevated.
If the Diagnosis is Confirmed
- For evaluation and ongoing collaborative management, consult Medical Genetics.
- Refer the family to Genetic Testing and Counseling.
- If the galactose-1-phosphate uridyltransferase and/or the GALT gene sequencing are consistent with classical galactosemia (GG genotype with low activity level), dietary restriction of galactose should continue. Patients with Duarte galactosemia do not require dietary restrictions. In Duarte galactosemia, the galactose-1-phosphate level may be elevated in the first year of life, but no deficits occur.
- Educate the family about the signs, symptoms, and the need for urgent care when the infant becomes ill.
- Assist in implementing and maintaining a rigid dietary exclusion of lactose and galactose.
- Monitor for developmental delays, speech delay, and, in females, ovarian failure.
- Assist in the patient’s developmental management, particularly with developmental and educational interventions as needed.
References
1. Therrell BL, Lloyd-Puryear MA, Camp KM, Mann MY. Inborn errors of metabolism identified via newborn screening: Ten-year incidence data and costs of nutritional interventions for research agenda planning. Mol Genet Metab. 2014;113(1-2):14-26. doi:10.1016/j.ymgme.2014.07.009
2. Freer DE, Ficicioglu C, Finegold D. Newborn screening for galactosemia: a review of 5 years of data and audit of a revised reporting approach. Clin Chem. 2010;56(3):437-444. doi:10.1373/clinchem.2009.135947
Article History
This article was originally published on the Medical Home Portal and updated before publication on TRiP. The Medical Home Portal, retired in July 2024, provided diagnosis and management information for pediatric conditions, guidance for immediate steps after a positive newborn screen result, and in-depth family education to improve outcomes for children with complex medical care needs. The full archive can be found at the Medical Home Portal Archive.
Topical Reviews in Pediatrics (TRIP) includes archival and updated content from the Medical Home Portal and features new, contemporary topics in pediatrics.
- 2022 revision: Brian Shayota, MDA
- 2012 revision: Kimberly Hart, MS, LCGCA
- 2007 first publication: Nicola Longo, MD, PhDA
AAuthor; CAContributing Author; SASenior Author; RReviewer
